Takeda renews commitment to Global Fund with JPY 350 Million Pledge

The Global Fund to Fight AIDS, Tuberculosis and Malaria has announced a new corporate pledge from Takeda Pharmaceutical Company.

The Japan-based pharmaceutical firm has committed JPY 350 million to support the Fund’s Eighth Replenishment.

This is the first corporate commitment to the new replenishment round. It will fund a two-year program that builds on the Takeda Initiative, a 15-year philanthropic partnership.

Takeda is the longest-standing corporate partner of the Global Fund. Since 2010, it has supported programs focused on disease prevention and health system strengthening in sub-Saharan Africa.

The Takeda Initiative, launched in 2010 with a total investment of JPY 2 billion, has aimed to improve maternal and child health.

The program integrates services for HIV, tuberculosis, and malaria into antenatal and postnatal care (ANC/PNC) in Kenya, Nigeria, and Tanzania.

Integration of these services helps in early detection and treatment.

This leads to healthier pregnancies and better outcomes for mothers and children.

Over the past five years alone, the Initiative has helped 1.5 million mothers receive quality care.

With the new commitment, Takeda will support efforts to scale and sustain the integrated care model.

The focus will remain on improving service delivery within ANC/PNC settings.

Takeda’s involvement with the Global Fund has extended to several initiatives.

These include the distribution of mosquito nets to fight malaria in Tanzania, expanding access to TB treatment in Kenya, and strengthening HIV services and awareness in Nigeria.

Each of these efforts aligns with Takeda’s goal to integrate services for better maternal and child health.

“For over 240 years, Takeda has prioritized patients and thoughtfully contributed to societal impact,” said Takako Ohyabu, Chief Global Corporate Affairs and Sustainability Officer at Takeda Pharmaceutical Company.

“Our long-standing collaboration with the Global Fund reflects this deeply rooted commitment,” she added.

“Through the Takeda Initiative, we have advanced systemic improvements in health care delivery for mothers and children in sub-Saharan Africa. With this renewed pledge, we remain committed to sustaining and scaling this impact by empowering local leadership and the health workforce for resilient health systems.”

She emphasized the importance of corporate involvement in global health:

“Our contribution underscores the vital role of the private sector in tackling global health challenges and driving lasting change, in close collaboration with stakeholders.”

Peter Sands, Executive Director of the Global Fund, welcomed the renewed support.

“The Takeda Initiative has demonstrated how innovation, commitment, and local ownership can transform health systems and improve lives, offering a powerful model for other corporate donors,” he said.

“We are deeply grateful to Takeda and call on corporate leaders and philanthropists to join us in supporting the Global Fund’s Eighth Replenishment,” Sands added. “Together, we can turn scientific breakthroughs into scalable solutions that protect the most vulnerable, strengthen health systems, and build a healthier world for generations to come.”

The Global Fund is aiming to raise US$2 billion from private donors during the Eighth Replenishment. It sees the private sector as a key player in transforming global health outcomes.

According to the Fund, every dollar invested yields an estimated US$19 in health gains and economic returns. The focus is on high-impact, sustainable solutions backed by innovation and private capital.

Takeda’s latest pledge reaffirms its role in global health philanthropy and its long-term partnership with the Global Fund.